Related Experiment Video

Updated: Jun 26, 2026

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons
09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

Impact of Genetic Polymorphisms on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Systematic Review

Nadeen S Sultan1, Ahmed S Alhallaq1, Mohammed S Alhallaq2

  • 1Laboratory Medicine Department, Faculty of Applied Medical Sciences, Al-Azhar University-Gaza, Gaza Strip, Palestine.

Asian Pacific Journal of Cancer Prevention : APJCP
|June 25, 2026
PubMed
Abstract

Insights

Genetic variations significantly influence bortezomib-induced peripheral neuropathy (BIPN) risk in multiple myeloma patients. Identifying these single-nucleotide polymorphisms (SNPs) may enable personalized treatments to prevent BIPN.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Neurology

Background:

  • Bortezomib is a key treatment for multiple myeloma.
  • Bortezomib-induced peripheral neuropathy (BIPN) is a common, serious side effect affecting 30-60% of patients.
  • BIPN involves sensory and sometimes motor nerve damage, impacting treatment and patient outcomes.

Purpose of the Study:

  • To investigate the genetic underpinnings of BIPN in multiple myeloma.
  • To identify specific single-nucleotide polymorphisms (SNPs) associated with BIPN risk or protection.

Main Methods:

  • A qualitative systematic review identified SNPs linked to BIPN.
  • Computational analyses (Gene Ontology, KEGG, PPI networks) explored implicated pathways.
  • SNP functional predictions (SIFT, PolyPhen-2) and evolutionary conservation were assessed.

Main Results:

  • 9 studies identified 48 risk-increasing SNPs and 21 protective SNPs for BIPN.
  • Associated genes are involved in xenobiotic response, detoxification, signal transduction, and inflammation.
  • Functional predictions and conservation analyses suggest the impact of certain variants on protein function.

Conclusions:

  • Genetic variants are likely crucial in BIPN development.
  • Findings support predictive genotyping for personalized strategies to mitigate BIPN in multiple myeloma.
Keywords:
BioinformaticsGenetic polymorphismbortezomibbortezomib-induced peripheral neuropathymultiple myeloma

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...